Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder

British Journal of Psychiatry

Volumn 203, Issue 5, 2013, Pages 358-365

  Lam, Raymond W ^a   Parikh, Sagar V ^b   Ramasubbu, Rajamannar ^c   Michalak, Erin E ^d   Tam, Edwin M ^d   Axler, Auby ^d   Yatham, Lakshmi N ^d   Kennedy, Sidney H ^b   Manjunath, Chinnapalli V ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM;

ADULT; AGED; AGITATION; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DSM-IV; FEMALE; HEADACHE; HEMORRHOID; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SCORING SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; TELEPHONE; XEROSTOMIA;

ADULT; AGED; CITALOPRAM; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; EMPLOYMENT; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; SELF REPORT; SEROTONIN UPTAKE INHIBITORS; TELEMEDICINE; YOUNG ADULT;

EID: 84887275287     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.112.125237     Document Type: Article

References (42)

1. Myette L, Garuso G, Stave G. Position Statement: Depression in the Working Population. American College of Occupational and Environmental Medicine, 2009.
2. Bender A, Farvolden P. Depression and the workplace: A progress report. Curr Psychiatry Rep 2008; 10: 73-9.
3. Kessler RC, Merikangas KR, Wang PS. The prevalence and correlates of workplace depression in the national comorbidity survey replication. J Occup Environ Med 2008; 50: 381-90.
4. Veronese A, Ayuso-Mateos JL, Cabello M, Chatterji S, Nuevo R. Work disability and depressive disorders: impact on the European population. Am J Phys Med Rehabil 2012; 91 (13 suppl 1): S62-8.
5. LaMontagne AD, Sanderson K, Cocker F. Estimating the Economic Benefits of Eliminating Job Strain as a Risk Factor for Depression. Victorian Heath Promotion Foundation, 2010.
6. World Health Organization. The Global Burden of Disease: 2004 Update. WHO, 2008. 7 Towers Watson. The Health and Productivity Advantage: 2009/2010 Staying@Work Report. Towers Watson, 2010.
7. Aronsson G, Gustafsson K. Sickness presenteeism: prevalence, attendance pressure factors, and an outline of a model for research. J Occup Environ Med 2005; 47: 958-66.
8. Collins JJ, Baase CM, Sharda CE, Ozminkowski RJ, Nicholson S, Billotti GM, et al. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med 2005; 47: 547-57.
9. Lerner D, Henke RM. What does research tell us about depression, job performance, and work productivity? J Occup Environ Med 2008; 50: 401-10.
10. Beck A, Crain AL, Solberg LI, Unutzer J, Glasgow RE, Maciosek MV, et al. Severity of depression and magnitude of productivity loss. Ann Fam Med 2011; 9: 305-11.
11. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med 2004; 46: 398-412.
12. Birnbaum HG, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, et al. Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States. J Occup Environ Med 2010; 52: 115-24.
13. Luo Z, Cowell AJ, Musuda YJ, Novak SP, Johnson EO. Course of major depressive disorder and labor market outcome disruption. J Ment Health Policy Econ 2010; 13: 135-49.
14. Dewa CS, Thompson AH, Jacobs P. The association of treatment of depressive episodes and work productivity. Can J Psychiatry 2011; 56: 743-50.
15. Nieuwenhuijsen K, Bultmann U, Neumeyer-Gromen A, Verhoeven AC, Verbeek JH, Feltz-Cornelis CM. Interventions to improve occupational health in depressed people. Cochrane Database Syst Rev 2008; 2: CD006237.
16. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord 2009; 117 (suppl 1): S1-S2.
17. Bee PE, Bower P, Lovell K, Gilbody S, Richards D, Feltz-Cornelis CM. Psychotherapy mediated by remote communication technologies: A meta-analytic review. BMC Psychiatry 2008; 8: 60.
18. Mohr DC, Ho J, Deffecy J, Reifler D, Sokol L, Burns MN, et al. Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients. A randomized trial. JAMA 2012; 307: 2278-85.
19. Simon GE, Ludman EJ, Tutty S, Operskalski B, Von Korff M. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: A randomized controlled trial. JAMA 2004; 292: 935-42.
20. Wang PS, Simon GE, Avorn J, Azocar F, Ludman EJ, McCulloch J, et al. Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: A randomized controlled trial. JAMA 2007; 298: 1401-11.
21. Parikh SV, Segal ZV, Grigoriadis S, Ravindran AV, Kennedy SH, Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone and in combination with antidepressant medications. J Affect Disord 2009; 117 (suppl 1): S15-S25.
22. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (suppl 20): 22-33.
23. Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: A meta-analysis. J Clin Psychiatry 2009; 70: 1219-29.
24. de Maat SM, Dekker J, Schoevers RA, de Jonghe F. Relative efficacy of psychotherapy and combined therapy in the treatment of depression: A meta-analysis. Eur Psychiatry 2007; 22: 1-8.
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
26. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care using the Sheehan Disability Scale. Int J Psychiatry Med 1997; 27: 93-105.
27. Lam RW, Michalak EE, Yatham LN. A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder. BMC Psychiatry 2009; 9: 78.
28. Kessler RC, Barber C, Beck A, Berglund P, Cleary PD, McKenas D, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med 2003; 45: 156-74.
29. Simon GE, Ludman EJ, Tutty S. Creating a Balance: A Step-By-Step Approach to Managing Stress and Lifting Your Mood. Trafford Publishing, 2006.
30. Tutty S, Ludman EJ, Simon G. Feasibility and acceptability of a telephone psychotherapy program for depressed adults treated in primary care. Gen Hosp Psychiatry 2005; 27: 400-10.
31. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976; 33: 1111-5.
32. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49: 761-8.
33. Mohr DC, Vella L, Hart S, Heckman T, Simon G. The effect of telephone administered psychotherapy on symptoms of depression and attrition: A meta-analysis. Clin Psychol (New York) 2008; 15: 243-53.
34. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet 2009; 373: 746-58.
35. Ali MK, Lam RW. Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2011; 7: 39-49.
36. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and functional improvement in employed depressed patients: A double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 2011; 31: 569-76.
37. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993: 4: 353-65.
38. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007; 23: 1605-14.
39. McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: A case for reassessing our goals in depression treatment research. Clin Psychol Rev 2009; 29: 243-59.
40. Greer TL, Kurian BT, Trivedi MH. Defining and measuring functional recovery from depression. CNS Drugs 2010; 24: 267-84.
41. Lam RW, Filteau MJ, Milev R. Clinical effectiveness: The importance of psychosocial functioning outcomes. J Affect Disord 2011; 132 (suppl 1): S9-S13.
42. Kessler RC, Ames M, Hymel PA, Loeppke R, McKenas DK, Richling DE, et al. Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med 2004; 46 (6 suppl): S23-S37.